Deepecho

Deepecho has developed an AI-powered software platform that automates and enhances fetal ultrasound diagnostics. The technology assists radiologists and minimally trained clinicians by providing automated measurements, standard plane recognition, teleguidance, and remote diagnosis. It aims to reduce neonatal mortality by improving early detection of complications such as fetal growth restriction, preeclampsia, low birth weight, preterm birth, and postpartum hemorrhage. The company’s research has been published in peer-reviewed journals including Nature Communications. Clinical trials are ongoing in Morocco and New York with promising results for accuracy in prenatal screening.